Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
Trials ; 14: 150, 2013 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-23702006

RESUMEN

BACKGROUND: Transfusion of red blood cells (RBC) is recommended in septic shock and the majority of these patients receive RBC transfusion in the intensive care unit (ICU). However, benefit and harm of RBCs have not been established in this group of high-risk patients. METHODS/DESIGN: The Transfusion Requirements in Septic Shock (TRISS) trial is a multicenter trial with assessor-blinded outcome assessment, randomising 1,000 patients with septic shock in 30 Scandinavian ICUs to receive transfusion with pre-storage leuko-depleted RBC suspended in saline-adenine-glucose and mannitol (SAGM) at haemoglobin level (Hb) of 7 g/dl or 9 g/dl, stratified by the presence of haematological malignancy and centre. The primary outcome measure is 90-day mortality. Secondary outcome measures are organ failure, ischaemic events, severe adverse reactions (SARs: anaphylactic reaction, acute haemolytic reaction and transfusion-related circulatory overload, and acute lung injury) and mortality at 28 days, 6 months and 1 year.The sample size will enable us to detect a 9% absolute difference in 90-day mortality assuming a 45% event rate with a type 1 error rate of 5% and power of 80%. An interim analysis will be performed after 500 patients, and the Data Monitoring and Safety Committee will recommend the trial be stopped if a group difference in 90-day mortality with P ≤0.001 is present at this point. DISCUSSION: The TRISS trial may bridge the gap between clinical practice and the lack of efficacy and safety data on RBC transfusion in septic shock patients. The effect of restrictive versus liberal RBC transfusion strategy on mortality, organ failure, ischaemic events and SARs will be evaluated.


Asunto(s)
Transfusión de Eritrocitos/métodos , Unidades de Cuidados Intensivos , Proyectos de Investigación , Choque Séptico/terapia , Biomarcadores/sangre , Protocolos Clínicos , Comités de Monitoreo de Datos de Ensayos Clínicos , Transfusión de Eritrocitos/efectos adversos , Transfusión de Eritrocitos/mortalidad , Fluidoterapia , Hemoglobinas/metabolismo , Humanos , Islandia , Medición de Riesgo , Factores de Riesgo , Países Escandinavos y Nórdicos , Choque Séptico/sangre , Choque Séptico/diagnóstico , Choque Séptico/mortalidad , Choque Séptico/fisiopatología , Factores de Tiempo , Resultado del Tratamiento
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA